GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » Other Operating Expense
中文

Geron (GERN) Other Operating Expense : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Geron Other Operating Expense?

Geron's Other Operating Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Geron's quarterly Other Operating Expense stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) and stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Geron's annual Other Operating Expense increased from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($0.00 Mil) but then declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).


Geron Other Operating Expense Historical Data

The historical data trend for Geron's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Other Operating Expense Chart

Geron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Geron Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Geron Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geron Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Geron's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Geron (GERN) Business Description

Traded in Other Exchanges
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.
Executives
Michelle Robertson officer: EVP, Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Scott Alan Samuels officer: EVP, Chief Legal Officer 919 E. HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
V Bryan Lawlis director
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
John A Scarlett director, officer: Chief Executive Officer C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Andrew J Grethlein officer: EVP, Technical Operations 651 GATEWAY BLVD STE 950, SOUTH SAN FRANCISCO CA 94080
Olivia Kyusuk Bloom officer: Controller, Chief Acctg Off C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
John F Mcdonald director C/O GERON CORPORATION, 919 EAST HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
Faye Feller officer: EVP, Chief Medical Officer 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA 94404
Anil Kapur officer: EVP, Corp Strategy & CCO 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Melissa Kelly officer: VP, Oncology 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Dawn Carter Bir director C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Aleksandra Rizo officer: EVP, Chief Medical Officer C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025